» Articles » PMID: 21310884

Outcomes of Hospitalisation for Right Heart Failure in Pulmonary Arterial Hypertension

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 2011 Feb 12
PMID 21310884
Citations 78
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study was to examine the causes and outcomes of hospitalisation in patients with pulmonary arterial hypertension (PAH). 205 consecutive hospitalisations occurring between 2000 and 2009 in 90 PAH patients were studied. The leading causes for hospitalisation were right heart failure (RHF; 56%), infection (16%) and bleeding disorders (8%). For patients with RHF, in-hospital mortality was 14% overall, 46% for patients receiving inotropes and 48% for those admitted to the intensive care unit. The predictors for in-hospital mortality were the presence of connective tissue disease (CTD) (OR 4.92), systolic blood pressure <100 mmHg (OR 4.32) and Na ≤ 136 mEq · L(-1) (OR 4.29). Mortality after discharge was 13, 26 and 35% at 3, 6 and 12 months, respectively. World Health Organization functional class prior to admission, renal dysfunction, Charlson comorbidity index, and the presence of CTD were all predictors of mortality after discharge. Hyponatraemia and low systolic blood pressure upon admission and underlying CTD are the main prognostic factors for in-hospital mortality in patients with PAH admitted for RHF. The short-term outcomes after discharge are poor and remarkably worse in patients with underlying CTD or renal impairment. Early recognition of these factors may guide decisions regarding more aggressive therapy, including consideration for lung transplantation.

Citing Articles

Circulating miRNA-486 as a novel diagnostic biomarker for right ventricular remodeling.

Cai H, Yu C, Li X, Wang X, Yang Y, Lan C Front Cardiovasc Med. 2025; 12:1518022.

PMID: 39944601 PMC: 11814203. DOI: 10.3389/fcvm.2025.1518022.


Proteomic Signatures of Right Ventricular Outcomes in Pulmonary Arterial Hypertension.

Pi H, Xia L, Boucherat O, Suresh K, Hemnes A, Bonnet S Circ Heart Fail. 2024; 17(11):e012067.

PMID: 39435559 PMC: 11576243. DOI: 10.1161/CIRCHEARTFAILURE.124.012067.


Transplantation, bridging, and support technologies in pulmonary hypertension.

Savale L, Benazzo A, Corris P, Keshavjee S, Levine D, Mercier O Eur Respir J. 2024; 64(4).

PMID: 39209471 PMC: 11525343. DOI: 10.1183/13993003.01193-2024.


Cardiac Arrhythmias in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Mechanistic Insights, Pathophysiology, and Outcomes.

Abouzaid A, Ali K, Jatoi S, Ahmed M, Ahmad G, Nazim A Ann Noninvasive Electrocardiol. 2024; 29(5):e70010.

PMID: 39205610 PMC: 11358588. DOI: 10.1111/anec.70010.


Use of multiomics to identify right ventricular disease states.

Nat Cardiovasc Res. 2024; 2(10):867-868.

PMID: 39196254 DOI: 10.1038/s44161-023-00340-9.